Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Mayne Pharma Group Limited
  6. Summary
    MYX   AU000000MYX0

MAYNE PHARMA GROUP LIMITED

(MYX)
  Report
End-of-day quote. End-of-day quote Australian Stock Exchange - 10/19
0.34 AUD   -2.86%
10/19MAYNE PHARMA : 2021 Corporate Governance Statement and Appendix 4G
PU
10/07MITHRA PHARMACEUTICALS S A : Provides FDA Update on Myring
AQ
10/07MAYNE PHARMA : Provides fda update on generic nuvaringo
AQ
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Australian Stock Exchange
10/13/2021 10/14/2021 10/15/2021 10/18/2021 10/19/2021 Date
0.31 0.3 0.31 0.35 0.34 Last
899894 2036419 918010 7923482 10733750 Volume
+1.64% -3.23% +3.33% +12.90% -2.86% Change
Estimated financial data (e)
Sales 2022 461 M 345 M 345 M
Net income 2022 -26,7 M -20,0 M -20,0 M
Net Debt 2022 257 M 193 M 193 M
P/E ratio 2022 -17,6x
Yield 2022 -
Sales 2023 563 M 422 M 422 M
Net income 2023 14,2 M 10,7 M 10,7 M
Net Debt 2023 255 M 191 M 191 M
P/E ratio 2023 39,2x
Yield 2023 -
Capitalization 600 M 449 M 449 M
EV / Sales 2022 1,86x
EV / Sales 2023 1,52x
Nbr of Employees 967
Free-Float 77,2%
More Financials
Company
Mayne Pharma Group Ltd is an Australia-based specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals. The Company’s segments include Generic Products (GPD), Specialty Products (SPD), Metrics Contract Services (MCS), and Mayne Pharma International (MPI). The GPD segment is engaged in the distribution of generic pharmaceutical products in the United States. GPD segment engaged... 
Sector
Pharmaceuticals
Calendar
11/23Shareholder meeting
More about the company
Ratings of Mayne Pharma Group Limited
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about MAYNE PHARMA GROUP LIMITED
10/19MAYNE PHARMA : 2021 Corporate Governance Statement and Appendix 4G
PU
10/07MITHRA PHARMACEUTICALS S A : Provides FDA Update on Myring
AQ
10/07MAYNE PHARMA : Provides fda update on generic nuvaringo
AQ
10/06MAYNE PHARMA : to Address US FDA Feedback on Generic Version of Birth Control Product
MT
10/06MAYNE PHARMA : 07/10/2021 Mayne Pharma provides FDA update on generic NUVARING
PU
10/06Mayne Pharma Provides US Food and Drug Administration Update on Generic NUVARING
CI
10/05MITHRA PHARMACEUTICALS S A : Announces the Appointment of its Representative to Mayne Phar..
AQ
10/04MAYNE PHARMA : appoints new Director
PU
10/03Mayne Pharma Group Limited Appoints Carolyn Myers to the Board
CI
09/30MAYNE PHARMA : Upsher-Smith Launches Three Additional Strengths of Isotretinoin Capsules
AQ
09/29MAYNE PHARMA : Adds generic absorica to us dermatology portfolio
AQ
09/28MAYNE PHARMA : Starts Distribution of Severe Acne Treatment Drug in US
MT
09/28MAYNE PHARMA : 29/09/2021 Mayne Pharma adds generic ABSORICA® to US portfolio
PU
09/28Mayne Pharma Enters into Private Label Supply and Distribution Agreement with Upsher-Sm..
CI
09/27MAYNE PHARMA : Notification regarding unquoted securities - MYX
PU
More news
News in other languages on MAYNE PHARMA GROUP LIMITED
10/07Brussel zet herstel door
10/07Brussel herstelt alweer
10/07BEURSBLIK : lancering Myring van Mithra nog steeds in 2023
10/07Lancering Myring van Mithra nog steeds in 2023
10/07BRUSSELS STOCK EXCHANGE : Scherp hogere opening Bel20 voorzien
More news
Chart MAYNE PHARMA GROUP LIMITED
Duration : Period :
Mayne Pharma Group Limited Technical Analysis Chart | MYX | AU000000MYX0 | MarketScreener
Technical analysis trends MAYNE PHARMA GROUP LIMITED
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 0,34 AUD
Average target price 0,45 AUD
Spread / Average Target 31,5%
EPS Revisions
Managers and Directors
Scott Richards Chief Executive Officer, MD & Executive Director
Peter Paltoglou Chief Financial Officer
Frank C. Condella Chairman
Gerard G. Nahum Chief Medical Officer
Keith Moore Vice President-Research & Development